Cargando…

Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis

AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or K...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wei-Xiang, Chen, Lingyan, Cao, Lu, Xu, Cheng, Cai, Gang, Chen, Jiayi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489376/
https://www.ncbi.nlm.nih.gov/pubmed/36147446
http://dx.doi.org/10.1155/2022/4364151
_version_ 1784792865213251584
author Qi, Wei-Xiang
Chen, Lingyan
Cao, Lu
Xu, Cheng
Cai, Gang
Chen, Jiayi
author_facet Qi, Wei-Xiang
Chen, Lingyan
Cao, Lu
Xu, Cheng
Cai, Gang
Chen, Jiayi
author_sort Qi, Wei-Xiang
collection PubMed
description AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or Ki-67 index. METHODS: Between January 2009 and December 2017, HER2-nonamplified BC in our single institute was identified. Patients were classified as HER2-low and HER2-0 cohort. Clinical characteristics were compared between these two groups and survival outcomes were calculated by the Kaplan–Meier method. We also performed subgroup analysis according to Ki-67 index and hormone-receptor (HR) status. RESULTS: Of the 2,230 included patients, 536 presented with HER2-0, and 1,694 with HER2-low positive. After a median follow-up of 85 months (range: 1–152 months), the 8-year OS, BCSS, and RFS of the overall cohort were 91%, 95%, and 89%, respectively. In comparison with the HER2-0 cohort, majority of HER2-low-expression BC concurrently presented with HR positive (82.3% vs. 69%, P < 0.001). There was no significant survival difference between the two groups in terms of OS, BCSS, and RFS (all p > 0.05). We then performed subgroup analysis according to HR status and Ki-67 index (<14% vs. ≥14%). Our results indicated that there was no significant survival difference between HER2-low-positive and HER2-0 tumors regardless of HR status (p > 0.05), while OS (p=0.026) and BCSS (p=0.052) of HER2-0 BC with high Ki-67 index were significantly poorer than that of HER2-low positive with high Ki-67, but not for RFS (p=0.17). CONCLUSION: Among early stage HER2-nonamplified BC, no significant survival difference could be found between HER2-low positive and HER2-0 cohort regardless of HR status. Survival outcomes of HER2-low positive with high Ki-67 seem to be poorer than that of HER2-0 tumors with high Ki-67 index.
format Online
Article
Text
id pubmed-9489376
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-94893762022-09-21 Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis Qi, Wei-Xiang Chen, Lingyan Cao, Lu Xu, Cheng Cai, Gang Chen, Jiayi J Oncol Research Article AIM: It has been reported that more than half of breast cancer (BC) could be identified as HER2-low-positive, which might be a distinct subtype. But the results are controversial. We aim to compare the survival outcomes between HER2-low-positive and HER2-0 BC with Asian women based on HR status or Ki-67 index. METHODS: Between January 2009 and December 2017, HER2-nonamplified BC in our single institute was identified. Patients were classified as HER2-low and HER2-0 cohort. Clinical characteristics were compared between these two groups and survival outcomes were calculated by the Kaplan–Meier method. We also performed subgroup analysis according to Ki-67 index and hormone-receptor (HR) status. RESULTS: Of the 2,230 included patients, 536 presented with HER2-0, and 1,694 with HER2-low positive. After a median follow-up of 85 months (range: 1–152 months), the 8-year OS, BCSS, and RFS of the overall cohort were 91%, 95%, and 89%, respectively. In comparison with the HER2-0 cohort, majority of HER2-low-expression BC concurrently presented with HR positive (82.3% vs. 69%, P < 0.001). There was no significant survival difference between the two groups in terms of OS, BCSS, and RFS (all p > 0.05). We then performed subgroup analysis according to HR status and Ki-67 index (<14% vs. ≥14%). Our results indicated that there was no significant survival difference between HER2-low-positive and HER2-0 tumors regardless of HR status (p > 0.05), while OS (p=0.026) and BCSS (p=0.052) of HER2-0 BC with high Ki-67 index were significantly poorer than that of HER2-low positive with high Ki-67, but not for RFS (p=0.17). CONCLUSION: Among early stage HER2-nonamplified BC, no significant survival difference could be found between HER2-low positive and HER2-0 cohort regardless of HR status. Survival outcomes of HER2-low positive with high Ki-67 seem to be poorer than that of HER2-0 tumors with high Ki-67 index. Hindawi 2022-09-13 /pmc/articles/PMC9489376/ /pubmed/36147446 http://dx.doi.org/10.1155/2022/4364151 Text en Copyright © 2022 Wei-Xiang Qi et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Qi, Wei-Xiang
Chen, Lingyan
Cao, Lu
Xu, Cheng
Cai, Gang
Chen, Jiayi
Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title_full Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title_fullStr Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title_full_unstemmed Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title_short Ki-67 Index Provides Long-Term Survival Information for Early-Stage HER2-Low-Positive Breast Cancer: A Single-Institute Retrospective Analysis
title_sort ki-67 index provides long-term survival information for early-stage her2-low-positive breast cancer: a single-institute retrospective analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489376/
https://www.ncbi.nlm.nih.gov/pubmed/36147446
http://dx.doi.org/10.1155/2022/4364151
work_keys_str_mv AT qiweixiang ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis
AT chenlingyan ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis
AT caolu ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis
AT xucheng ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis
AT caigang ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis
AT chenjiayi ki67indexprovideslongtermsurvivalinformationforearlystageher2lowpositivebreastcancerasingleinstituteretrospectiveanalysis